Skip to content
Riskpilot
← Tilbage til søgning
Log ind
Få fuld adgang
Melius Pharma AB
AB
Active
Org 5593323669
Rönninge Skolväg 9 B, 144 62
Rönninge
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2021 · 4 years old
0 ansatte
Overvåg
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Melius Pharma AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
0M
-1M
-1M
0M
2022
0M
0%
2023
0M
0%
2024
EBITDA
SEK millions
0M
-4M
-8M
-12M
-16M
-4M
2022
-11M
-175%
2023
-13M
-18%
2024
Income statement
SEK thousands
Item
2022
2023
2024
Revenue
0
37
0
Staff expenses
—
—
—
EBITDA
−4 330
−10 503
−12 694
Depreciation & amort.
−0
−0
−0
EBIT
−4 330
−10 503
−12 694
Net financials
—
11
−66
Profit before tax
−4 330
−10 492
−12 727
Tax
−0
−0
−0
Net profit
−4 330
−10 492
−12 727
Balance sheet
SEK thousands
Item
2022
2023
2024
Total assets
17 892
5 178
3 092
Equity
14 217
3 794
2 066
Long-term debt
0
0
0
Short-term debt
3 675
1 385
1 026
Total debt
3 675
1 385
1 026
Financial ratios
5-year trend
EBITDA-margin
-1269400000.0%
Denne virksomhed
15.8%
Markedsmedian
8034177315% under markedet
2022
2024
Soliditetsgrad
66.8%
Denne virksomhed
38.2%
Markedsmedian
75% over markedet
2022
2024
Egenkapitalforrentning
-616.0%
Denne virksomhed
18.4%
Markedsmedian
3448% under markedet
2022
2024
Nettoresultatgrad
-1272700000.0%
Denne virksomhed
8.1%
Markedsmedian
15712345779% under markedet
2022
2024
Aktivomsætning
0.00×
Denne virksomhed
1.12×
Markedsmedian
100% under markedet
2022
2024
Gæld/egenkapital
0.50×
Denne virksomhed
0.62×
Markedsmedian
19% under markedet
2022
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2021-08-01 – 2022-12-31
View
PDF
More on Melius Pharma AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
